| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 60MM | - |
| Operating Income | -24MM | -52% |
| Operating Expenses | 84MM | +51% |
| Net Income | -18.9MM | -58% |
| R&D | 69.6MM | +72% |
| G&A | 14.5MM | -4% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Two-year extension for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseasesCAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE: BMY) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer
In this piece, we will take a look at the 12 under the radar stocks with massive upside for 2024. If you want to skip our overview of shareholder ownership and how shares can jump if they come ‘over’ the radar instead of under, then you can jump ahead to 5 Under-the-Radar Stocks With Massive […]
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., April 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that three abstracts have been accepted for presentation, including one oral presentation, at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 7 – 11, 2024, in Baltimore, MD, and virtually. The Company is presenting pre-clinical data to support its development of transformative in vivo gene editing medicin
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The company now has a chance to get its lead program out the door a bit sooner.
Editas Medicine Inc (NASDAQ:EDIT), a leading genome editing company, focuses on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world.
The biotech has bounced back some in the past year.
The clinical-stage genome editing company dropped a couple of important announcements for shareholders.
Editas Medicine, Inc. ( NASDAQ:EDIT ) just released its latest full-year results and things are looking bullish...